Prevention of TGFβ induction attenuates angII -stimulated vascular biglycan and atherosclerosis in Ldlr-/- mice1

Journal of Lipid Research

Volumn 54, Issue 8, 2013, Pages 2255-2264

  Tang, Tao ^a,b   Wilson, Patricia G ^a,b   Thompson, Joel C ^a,b   Nelson, Christina ^a   Yoder, Meghan H ^a   Tannock, Lisa R ^a,b,c  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Angiotensin II; Atherosclerosis initiation; Biglycan apoB colocalization; Low density lipoprotein retention; Proteoglycans; Renin angiotensin system; TGF neutralizing antibody

Indexed keywords

ANGIOTENSIN II; APOLIPOPROTEIN B; BIGLYCAN; CD45 ANTIGEN; CD68 ANTIGEN; CHOLESTEROL; COLLAGEN; NEUTRALIZING ANTIBODY; PERLECAN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA OCCLUSION; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LIPID STORAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS INHIBITION; SYSTOLIC BLOOD PRESSURE;

EID: 84881226028     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.P040139     Document Type: Article

References (55)

1. Schmieder, R. E., K. F. Hilgers, M. P. Schlaich, and B. M. Schmidt. 2007.Renin-angiotensin system and cardiovascular risk. Lancet. 369 : 1208-1219.
2. Daugherty, A., and L. Cassis.1999.Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor-/-mice. Ann. N. Y. Acad. Sci. 892 : 108-118.
3. Candido, R., K. A. Jandeleit-Dahm, Z. Cao, S. P. Nesteroff, W. C. Burns, S. M. Twigg, R. J. Dilley, M. E. Cooper, and T. J. Allen.2002. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation.106 : 246-253.
4. Fox, K. M. 2003.Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet.362 : 782-788.
5. Yusuf, S., P. Sleight, J. Pogue, J. Bosch, R. Davies, and G. Dagenais. 2000.Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342 : 145-153.
6. Boring, L., J. Gosling, M. Cleary, and I. F. Charo.1998.Decreased lesion formation in CCR2-/-mice reveals a role for chemokines in the initiation of atherosclerosis. Nature.394 : 894-897.
7. Kranzhöfer, R., M. Browatzki, J. Schmidt, and W. Kübler.1999. Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem. Biophys. Res. Commun. 257 : 826-828.
8. Griendling, K. K., C. A. Minieri, J. D. Ollerenshaw, and R. W. Alexander.1994.Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74 : 1141-1148.
9. Wassmann, S., T. Czech, M. van Eickels, I. Fleming, M. Bohm, and G. Nickenig.2004.Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation.110 : 3062-3067.
10. Kato, H., H. Suzuki, S. Tajima, Y. Ogata, T. Tominaga, A. Sato, and T. Saruta.1991.Angiotensin II stimulates collagen synthesis in cultured vascular smooth muscle cells. J. Hypertens. 9 : 17-22.
11. Regenass, S., T. J. Resink, F. Kern, F. R. Buhler, and A. W. Hahn. 1994.Angiotensin-II-induced expression of laminin complex and laminin A-chain-related transcripts in vascular smooth muscle cells. J. Vasc. Res. 31 : 163-172.
12. Figueroa, J. E., and P. Vijayagopal.2002.Angiotensin II stimulates synthesis of vascular smooth muscle cell proteoglycans with enhanced low density lipoprotein binding properties. Atherosclerosis. 162 : 261-268.
13. Williams, K. J., and I. Tabas.1995.The response-to-retention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15 : 551-561.
14. Tannock, L. R., and V. L. King.2008.Proteoglycan mediated lipoprotein retention: A mechanism of diabetic atherosclerosis. Rev. Endocr. Metab. Disord. 9 : 289-300.
15. Olin-Lewis, K., R. M. Krauss, M. La Belle, P. J. Blanche, P. H. Barrett, T. N. Wight, and A. Chait.2002.ApoC-III content of apoBcontaining lipoproteins is associated with binding to the vascular proteoglycan biglycan. J. Lipid Res. 43 : 1969-1977.
16. Kunjathoor, V. V., D. S. Chiu, K. D. O'Brien, and R. C. LeBoeuf. 2002.Accumulation of biglycan and perlecan, but not versican, in lesions of murine models of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22 : 462-468.
17. O'Brien, K. D., K. L. Olin, C. E. Alpers, W. Chiu, M. Ferguson, K. Hudkins, T. N. Wight, and A. Chait.1998.Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: Colocalization of biglycan with apolipoproteins. Circulation.98 : 519-527.
18. Nakashima, Y., H. Fujii, S. Sumiyoshi, T. N. Wight, and K. Sueishi. 2007.Early human atherosclerosis: Accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler. Thromb. Vasc. Biol. 27 : 1159-1165.
19. O'Brien, K. D., K. Lewis, J. W. Fischer, P. Johnson, J. Y. Hwang, E. A. Knopp, M. G. Kinsella, P. H. Barrett, A. Chait, and T. N. Wight. 2004.Smooth muscle cell biglycan overexpression results in increased lipoprotein retention on extracellular matrix: Implications for the retention of lipoproteins in atherosclerosis. Atherosclerosis. 177 : 29-35.
20. Skålén, K., M. Gustafsson, E. K. Rydberg, L. M. Hultén, O. Wiklund, T. L. Innerarity, and J. Borén.2002. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature.417 : 750-754.
21. Huang, F., J. C. Thompson, P. G. Wilson, H. H. Aung, J. C. Rutledge, and L. R. Tannock.2008.Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development. J. Lipid Res. 49 : 521-530.
22. Nagy, N., A. Melchior-Becker, and J. W. Fischer.2010.Long-term treatment with the AT1-receptor antagonist telmisartan inhibits biglycan accumulation in murine atherosclerosis. Basic Res. Cardiol. 105 : 29-38.
23. Little, P. J., L. Tannock, K. L. Olin, A. Chait, and T. N. Wight.2002. Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta1 exhibit increased binding to LDLs. Arterioscler. Thromb. Vasc. Biol. 22 : 55-60.
24. Kähäri, V. M., H. Larjava, and J. Uitto.1991.Differential regulation of extracellular matrix proteoglycan (PG) gene expression. Transforming growth factor-beta 1 up-regulates biglycan (PGI), and versican (large fibroblast PG) but down-regulates decorin (PGII) mRNA levels in human fibroblasts in culture. J. Biol. Chem. 266 : 10608-10615.
25. Schönherr, E., H. T. Järveläinen, M. G. Kinsella, L. J. Sandell, and T. N. Wight.1993.Platelet-derived growth factor and transforming growth factor-beta 1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells. Arterioscler. Thromb. 13: 1026-1036.
26. Kagami, S., W. A. Border, D. E. Miller, and N. A. Noble.1994. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J. Clin. Invest. 93 : 2431-2437.
27. Tiede, K., K. Stoter, C. Petrik, W. B. Chen, H. Ungefroren, M. L. Kruse, M. Stoll, T. Unger, and J. W. Fischer.2003.Angiotensin II AT(1)-receptor induces biglycan in neonatal cardiac fibroblasts via autocrine release of TGFbeta in vitro. Cardiovasc. Res. 60 : 538-546.
28. Daugherty, A., M. W. Manning, and L. A. Cassis.2000.Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J. Clin. Invest. 105 : 1605-1612.
29. Junqueira, L. C., G. Bignolas, and R. R. Brentani.1979.Picrosirius staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem. J. 11 : 447-455.
30. Zhou, X., T. P. Johnston, D. Johansson, P. Parini, K. Funa, J. Svensson, and G. K. Hansson.2009.Hypercholesterolemia leads to elevated TGF-beta1 activity and T helper 3-dependent autoimmune responses in atherosclerotic mice. Atherosclerosis.204 : 381-387.
31. Grainger, D. J. 2004.Transforming growth factor beta and atherosclerosis: So far, so good for the protective cytokine hypothesis. Arterioscler. Thromb. Vasc. Biol. 24 : 399-404.
32. Grainger, D. J., P. R. Kemp, J. C. Metcalfe, A. C. Liu, R. M. Lawn, N. R. Williams, A. A. Grace, P. M. Schofield, and A. Chauhan.1995. The serum concentration of active transforming growth factorbeta is severely depressed in advanced atherosclerosis. Nat. Med. 1 : 74-79.
33. Grainger, D. J., D. E. Mosedale, J. C. Metcalfe, and E. P. Bottinger. 2000.Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions. J. Cell Sci. 113 : 2355-2361.
34. Mallat, Z., A. Gojova, C. Marchiol-Fournigault, B. Esposito, C. Kamate, R. Merval, D. Fradelizi, and A. Tedgui.2001.Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ. Res. 89 : 930-934.
35. Lutgens, E., M. Gijbels, M. Smook, P. Heeringa, P. Gotwals, V. E. Koteliansky, and M. J. Daemen.2002.Transforming growth factorbeta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler. Thromb. Vasc. Biol. 22 : 975-982.
36. Wang, Y., H. Ait-Oufella, O. Herbin, P. Bonnin, B. Ramkhelawon, S. Taleb, J. Huang, G. Offenstadt, C. Combadiere, L. Renia, et al. 2010.TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II-infused mice. J. Clin. Invest. 120 : 422-432.
37. Robertson, A. K., M. Rudling, X. Zhou, L. Gorelik, R. A. Flavell, and G. K. Hansson.2003.Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J. Clin. Invest. 112 : 1342-1350.
38. Li, D., Y. Liu, J. Chen, N. Velchala, F. Amani, A. Nemarkommula, K. Chen, H. Rayaz, D. Zhang, H. Liu, et al.2006.Suppression of atherogenesis by delivery of TGFbeta1ACT using adeno-associated virus type 2 in LDLR knockout mice. Biochem. Biophys. Res. Commun. 344 : 701-707.
39. Frutkin, A. D., G. Otsuka, A. Stempien-Otero, C. Sesti, L. Du, M. Jaffe, H. L. Dichek, C. J. Pennington, D. R. Edwards, M. Nieves-Cintron, et al.2009.TGF-[beta]1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 29 : 1251-1257.
40. Nabel, E. G., L. Shum, V. J. Pompili, Z. Y. Yang, H. San, H. B. Shu, S. Liptay, L. Gold, D. Gordon, R. Derynck, et al.1993.Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc. Natl. Acad. Sci. USA.90 : 10759-10763.
41. Buday, A., P. Orsy, M. Godo, M. Mozes, G. Kokeny, Z. Lacza, A. Koller, Z. Ungvari, M. L. Gross, Z. Benyo, et al.2010.Elevated systemic TGF-beta impairs aortic vasomotor function through activation of NADPH oxidase-driven superoxide production and leads to hypertension, myocardial remodeling, and increased plaque formation in apoE(-/-) mice. Am. J. Physiol. Heart Circ. Physiol. 299 : H386-H395.
42. Grainger, D. J. 2007.TGF-beta and atherosclerosis in man. Cardiovasc. Res. 74 : 213-222.
43. Tiede, K., A. Melchior-Becker, and J. W. Fischer.2010.Transcriptional and posttranscriptional regulators of biglycan in cardiac fibroblasts. Basic Res. Cardiol. 105 : 99-108.
44. Heeneman, S., J. Haendeler, Y. Saito, M. Ishida, and B. C. Berk. 2000.Angiotensin II induces transactivation of two different populations of the platelet-derived growth factor beta receptor. Key role for the p66 adaptor protein Shc. J. Biol. Chem. 275 : 15926-15932.
45. Wang, C., L. L. Wu, J. Liu, Z. G. Zhang, D. Fan, and L. Li.2008. Crosstalk between angiotensin II and platelet derived growth factor-BB mediated signal pathways in cardiomyocytes. Chin. Med. J. (Engl.).121 : 236-240.
46. Daugherty, A., H. Lu, D. L. Rateri, and L. A. Cassis.2008. Augmentation of the renin-angiotensin system by hypercholesterolemia promotes vascular diseases. Future Lipidol. 3 : 625-636.
47. Vikramadithyan, R. K., Y. Kako, G. Chen, Y. Hu, E. Arikawa-Hirasawa, Y. Yamada, and I. J. Goldberg.2004.Atherosclerosis in perlecan heterozygous mice. J. Lipid Res. 45 : 1806-1812.
48. Tran-Lundmark, K., P. K. Tran, G. Paulsson-Berne, V. Friden, R. Soininen, K. Tryggvason, T. N. Wight, M. G. Kinsella, J. Boren, and U. Hedin.2008.Heparan sulfate in perlecan promotes mouse atherosclerosis: Roles in lipid permeability, lipid retention, and smooth muscle cell proliferation. Circ. Res. 103 : 43-52.
49. Hollmann, J., A. Schmidt, D. B. von Bassewitz, and E. Buddecke. 1989.Relationship of sulfated glycosaminoglycans and cholesterol content in normal and arteriosclerotic human aorta. Arteriosclerosis. 9 : 154-158.
50. Tran, P. K., H. E. Agardh, K. Tran-Lundmark, J. Ekstrand, J. Roy, B. Henderson, A. Gabrielsen, G. K. Hansson, J. Swedenborg, G. Paulsson-Berne, et al.2007.Reduced perlecan expression and accumulation in human carotid atherosclerotic lesions. Atherosclerosis. 190 : 264-270.
51. Chen, J. K., H. Hoshi, and W. L. McKeehan.1987.Transforming growth factor type beta specifically stimulates synthesis of proteoglycan in human adult arterial smooth muscle cells. Proc. Natl. Acad. Sci. USA.84 : 5287-5291.
52. Kaji, T., A. Yamada, S. Miyajima, C. Yamamoto, Y. Fujiwara, T. N. Wight, and M. G. Kinsella.2000.Cell density-dependent regulation of proteoglycan synthesis by transforming growth factor-beta(1) in cultured bovine aortic endothelial cells. J. Biol. Chem. 275 : 1463-1470.
53. Bassols, A., and J. Massague.1988.Transforming growth factor beta regulates the expression and structure of extracellular matrix chondroitin/dermatan sulfate proteoglycans. J. Biol. Chem. 263 : 3039-3045.
54. Dreher, K. L., V. Asundi, D. Matzura, and K. Cowan.1990.Vascular smooth muscle biglycan represents a highly conserved proteoglycan within the arterial wall. Eur. J. Cell Biol. 53 : 296-304.
55. Evanko, S. P., E. W. Raines, R. Ross, L. I. Gold, and T. N. Wight. 1998.Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-beta. Am. J. Pathol. 152 : 533-546.